IMarkHD: in Vivo Longitudinal Imaging of HD Pathology

Sponsor
King's College London
Study ID
NCT03434548
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • PET imaging — RADIATION
    PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain.
  • Multi-modal MRI imaging — OTHER
    Multi-modal MRI imaging

Study Details

iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in participants' brains, ranging from several years before symptom onset to the advanced symptom stage. The study will be conducted over a three (3) year period (Baseline, Year-1, and Year-2).

Key Dates

First listed
Feb 15, 2018
Start date
Jul 20, 2021
Status verified
Mar 2025
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
113 participants (estimated)

Arms

  • Arm: Cohort 1
    Healthy controls. Multi-modal MRI imaging.
  • Arm: Cohort 2
    People with Huntington's (without symptoms, early disease stage, and later disease stage), and healthy controls People with HD divided in groups according to disease stage: * Without symptoms (approximately HD-ISS stage 0 or 1) * Early disease (approximately HD-ISS stage 2) * Later disease stage (approximately HD-ISS stage 3)

Primary Outcome Measure

Primary outcome measure 1 [ Time Frame: 2 years ]

Central Contacts

Find similar trials

Nationwide
Huntington disease trialsNeurology trialsBrain disorders trials

Related Studies